Advanced Hepatocellular Carcinoma Pipeline Insight
DelveInsight’s, “Advanced Hepatocellular Carcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Hepatocellular Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Advanced Hepatocellular Carcinoma Understanding
Advanced Hepatocellular Carcinoma: Overview
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death. HCC is almost invariably associated with underlying risk factors, such as chronic infections with hepatitis B (HBV) or C (HCV), metabolic syndrome, and alcohol abuse. Many patients present with advanced-stage disease defined as Barcelona Clinic Liver Cancer (BCLC) stage C: cancer-related symptoms (performance status 1–2), preserved liver function, and portal invasion or extrahepatic spread (EHS). These patients have a poor prognosis. Without treatment, the median overall survival (OS) of patients included in the SHARP trial (mixing BCLC B progressing after TACE and BCLC C patients) is around 8 months. In the SHARP trial, the subgroup of BCLC C patients in the placebo arm had a median OS of 7 months, whereas BCLC B patients had a median OS of 11.4 months.
"Advanced Hepatocellular Carcinoma - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Hepatocellular Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Hepatocellular Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Hepatocellular Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Hepatocellular Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Hepatocellular Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Hepatocellular Carcinoma.
Advanced Hepatocellular Carcinoma Emerging Drugs Chapters
This segment of the Advanced Hepatocellular Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Hepatocellular Carcinoma Emerging Drugs
CS1003: CStone Pharmaceuticals
CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1), which is being developed for immunotherapy of various tumors. Compared to most of the anti-PD-1 monoclonal antibodies that bind to human and monkey PD-1 (those that have either been approved or are being investigated in clinical trials), CS1003 can bind to both human and murine PD-1, and has shown unique competitive advantages in synergistic mouse models for drug efficacy testing.
AK104 is a potential next-generation, first-in-class humanized IgG1 tetrameric bi-specific antibody drug candidate that is based on Akeso's proprietary ""TETRABODY"" technology and simultaneously targets two immune checkpoint molecules: PD-1 and CTLA-4. PD-1 and CTLA-4 co-express in tumor infiltrating lymphocytes (TILs), but not in normal peripheral tissues. AK104 is in a tetrameric form, which is designed to bind to PD-1 and CTLA-4 simultaneously to achieve the efficacy of PD-1 and CTLA-4 combination blockade with lowered toxicity.
Further product details are provided in the report……..
Advanced Hepatocellular Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Advanced Hepatocellular Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Advanced Hepatocellular Carcinoma
There are approx. 50+ key companies which are developing the therapies for Advanced Hepatocellular Carcinoma. The companies which have their Advanced Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase III include, CStone Pharmaceuticals.
DelveInsight’s report covers around 50+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Advanced Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Advanced Hepatocellular Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Hepatocellular Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Hepatocellular Carcinoma drugs.
Advanced Hepatocellular Carcinoma Report Insights
- Advanced Hepatocellular Carcinoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Advanced Hepatocellular Carcinoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Advanced Hepatocellular Carcinoma drugs?
- How many Advanced Hepatocellular Carcinoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Hepatocellular Carcinoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Hepatocellular Carcinoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Advanced Hepatocellular Carcinoma and their status?
- What are the key designations that have been granted to the emerging drugs?